{"filings":[{"id":68287,"accession_number":"0001493152-26-022727","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-05-13T20:11:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.","Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.","Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.","Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.","Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs."],"consensus_eps_estimate":-0.0408,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1110956.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102020,"accession_number":"0001493152-26-013405","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq deficiency notice for continued listing rule non-compliance","event_type":"other_material","confidence":"high","bullets":["Received notice on March 27, 2026 for non-compliance with Nasdaq Listing Rule 5550(b) requiring $2.5M equity, $35M market value, or $500K net income.","Company has 45 days to submit a compliance plan; cure period up to 180 days if plan accepted.","Also remains non-compliant with minimum bid price rule (need $1.00) until June 17, 2026.","Failure to cure either deficiency could lead to delisting of common stock from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102019,"accession_number":"0001493152-26-012673","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M","event_type":"earnings","confidence":"high","bullets":["Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.","Revenue fell to $3.09M from $3.50M; net loss widened to $7.36M ($0.23/sh) from $5.81M ($0.20/sh).","Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant; Dyadic eligible for profit share.","Expanded Fermbox Bio collaboration; commercial launch of recombinant DNase I (RNase-free).","OEM distribution agreement with IBT Bioservices for DNase I and transferrin; BRIG Bio deal for alpha-lactalbumin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102018,"accession_number":"0001493152-26-009179","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic International enters into ATM equity distribution agreement for up to $4.24M with Craig-Hallum","event_type":"other_material","confidence":"high","bullets":["ATM facility allows Dyadic to sell up to $4,237,818 of common stock at prevailing market prices through Craig-Hallum as sales agent.","Craig-Hallum will receive up to 3.0% commission on gross sales price; Dyadic also reimburses certain expenses and provides indemnification.","No obligation to sell any shares; Company may suspend or terminate the offering at any time.","Shares are offered under effective S-3 shelf registration statement (Aug 2023) and prospectus supplement dated March 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118363,"accession_number":"0001493152-25-029351","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic extends convertible note maturity to Dec 2027, conversion price set at $1.05","event_type":"debt","confidence":"high","bullets":["Maturity of Senior Secured Convertible Notes extended from March 8, 2027 to December 31, 2027.","Conversion price amended to $1.05 per share of common stock.","Holders lose optional redemption right except in event of default under the notes.","Amendment dated December 23, 2025; affects existing notes due March 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118362,"accession_number":"0001493152-25-029141","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq minimum bid price deficiency notice; 180-day cure period through June 17, 2026","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Dec 19, 2025; bid price below $1 for 30 consecutive business days.","Company has 180 calendar days, until June 17, 2026, to regain compliance by closing at $1+ for 10 consecutive days.","If not compliant by deadline, may qualify for additional 180-day period subject to meeting other listing criteria.","No immediate impact on Nasdaq Capital Market listing; company evaluating options to cure bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118361,"accession_number":"0001493152-25-021914","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic International Reports Q3 2025 Financial Results and Strategic Progress","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.","Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.","Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.","Secured ERS Genomics CRISPR license to optimize protein production.","Received $1.5 million in milestone payments from Proliant for animal-free serum albumin."],"consensus_eps_estimate":-0.0442,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2524819.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118360,"accession_number":"0001493152-25-017306","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.","Received $500K milestone from Proliant for recombinant human albumin productivity; payment expected Q4 2025; commercial launch targeted late 2025/early 2026.","Received $250K milestone payment from Inzymes for dairy enzyme productivity improvements; first enzyme scale-up on track for late 2025 launch.","Signed term sheet for development of non-animal human alpha-lactalbumin for infant nutrition; sampling of bovine version underway.","Advancing commercialization of recombinant transferrin and DNase I with ongoing sampling and validation in research/diagnostic markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134802,"accession_number":"0001493152-25-013635","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic amends security agreement; CEO's trust added as secured party for $1M note purchase","event_type":"debt","confidence":"high","bullets":["CEO Mark Emalfarb purchased and was assigned a $1,000,000 Senior Secured Convertible Promissory Note due March 8, 2027.","Amendment added Mark A. Emalfarb Trust as a secured party with $1,000,000 principal.","Other secured parties updated: Francisco Trust $1M, Barry M. Kitt $1M, CK Management $1M, and others.","Amendment executed September 15, 2025, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134801,"accession_number":"0001641172-25-023496","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).","Cash $7.3M at June 30; $5.3M net from August 1 equity offering (6.052M shares at $0.95).","Rebranded as Dyadic Applied BioSolutions; targeting 2025 commercial launch of animal-free serum albumin with Proliant.","Received $1.5M second installment from Gates Foundation mAb grant; expects $500K Proliant milestone in Q3 2025.","Inzymes milestone $250K received; EN3ZYME enzyme cocktail launched with Fermbox Bio under revenue share."],"consensus_eps_estimate":-0.0612,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1360202.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134800,"accession_number":"0001641172-25-021911","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyadic International prices 6.05M-share public offering at $0.95, net ~$5.3M","event_type":"other_material","confidence":"high","bullets":["Offering of 6,052,000 shares at $0.95 per share; expected net proceeds approximately $5.3 million.","Craig-Hallum Capital Group LLC acting as sole managing underwriter.","Net proceeds to be used for working capital, product development, sales and marketing.","Offering closed on August 1, 2025; shelf registration effective August 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134799,"accession_number":"0001641172-25-020731","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic posts strategic presentation; no specific financial or operational updates","event_type":"other_material","confidence":"low","bullets":["Presentation posted July 23, 2025 highlights transition from research to commercial focus.","Focus on C1 and Dapibus gene expression platforms for non-therapeutic protein production.","No specific financial targets, revenue guidance, or operational metrics disclosed.","Presentation will be used at industry and investor conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134798,"accession_number":"0001641172-25-020728","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Dyadic that its common stock bid price closed below $1 for 30 consecutive business days, violating Listing Rule 5550(a)(2).","Company has until January 13, 2026 to regain compliance by having bid price close at $1 or more for 10 consecutive trading days.","Dyadic also remains out of compliance with the $35 million minimum Market Value of Listed Securities (MVLS) requirement, with a separate cure deadline of December 20, 2025.","The Company plans to monitor its bid price and evaluate available options to cure the deficiency.","Failure to cure either deficiency could lead to delisting; the Company may appeal any delisting determination to a Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134797,"accession_number":"0001437749-25-021978","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant","event_type":"other_material","confidence":"high","bullets":["Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.","Reports $250,000 milestone payment for second non-animal dairy enzyme program.","Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.","Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.","Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151719,"accession_number":"0001437749-25-021420","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq deficiency notice for MVLS below $35M threshold","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff notified Dyadic on June 23 that MVLS was below $35M for 30 consecutive business days.","Company has until December 20, 2025 to regain compliance by closing at $35M+ for 10 consecutive days.","If compliance not achieved, common stock may be delisted; company plans to evaluate options.","Notice has no immediate effect on DYAI listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151718,"accession_number":"0001437749-25-021169","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyadic shareholders re-elect Emalfarb, ratify Crowe, and adopt annual say-on-pay at 2025 meeting","event_type":"other","confidence":"high","bullets":["Mark A. Emalfarb re-elected Class III director with 15,946,385 votes for, 421,896 withheld; 7,892,709 broker non-votes.","Ratification of Crowe LLP as independent auditor passed with 24,013,307 for, 237,523 against, 10,160 abstain.","Advisory say-on-pay vote approved: 15,765,072 for, 522,744 against, 80,465 abstain; 7,892,709 broker non-votes.","Say-on-pay frequency: 15,443,558 votes for 1-year; Board sets future advisory votes every one year.","All four proposals passed at the June 20, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151717,"accession_number":"0001437749-25-019177","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Dyadic appoints Joe Hazelton as President; strategic shift to ancillary proteins with commercial partnerships","event_type":"leadership","confidence":"high","bullets":["Hazelton promoted to President, continues as COO; base salary raised 10% to $320,000; 25,000-share option grant with 4-year vesting.","Strategic pivot to ancillary recombinant proteins for life sciences, nutrition, and industrial markets; validated by partnerships with Proliant Health, dairy enzyme firm, and EN3ZYME.","Legacy biopharma programs remain active under CEO Emalfarb; company to pursue corporate rebranding.","CEO states milestones validate strategy; Hazelton to scale commercialization and drive operational execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}